Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biological medicine helps more people with rheumatoid arthritis

13.06.2008
Patients who have recently developed rheumatoid arthritis respond better to treatment with biological medicine in combination with conventional pharmacological medicine.

This according to results of the Swefot national clinical study, which is to be presented at an international rheumatology congress in Paris by scientists from Swedish Karolinska Institutet and Karolinska University Hospital, who conducted the study in association with another 15 rheumatology units in Sweden.

Some 60,000 people in Sweden have rheumatoid arthritis, and another 1,500 develop the disease every year. The symptoms are swollen, tender joints and impaired mobility. Some patients respond poorly to medical treatment and/or develop side effects. The Swefot study, which was launched in 2002, shows that a certain combination of pharmacological medicines and new biological medicines is more efficacious on these patients.

“After the disease has been confirmed in a patient, we start by treating it with Methotrexate, MTX,” says Ronald van Vollenhoven, Associate Professor and Senior Physician, and member of the study’s steering committee. “But for the group of patients who don’t respond well to MTX, it’s more effective to add a biological medicine than to combine MTX with an older drug.”

Biological medicines are a new group of drugs that have been in use for ten years and that are produced using modern DNA-based methods. What makes them special is that they can be designed to target a specific goal, which makes them more efficacious and reduces the risk of adverse reaction. They can only be injected and are complicated to produce, which means that the cost of a drug for one patient can exceed 100,000 kronor a year.

“Biological medicines have revolutionised rheumatologic therapy, but there are still some concerns, as the long-term effects are not fully known, and these medications are very expensive”, says Dr van Vollenhoven. “The Swefot trial is the first study in which the addition of biological treatment is compared directly to the addition of conventional antirheumatic medications.”

The study involved 487 patients, who had developed rheumatoid arthritis in the previous year. First they were treated with the most established anti-rheumatic medicine Methotrexate (MTX); after three or four months, the 258 patients who did not respond well to MTX were divided randomly into two treatment groups. Group A received a combination treatment with MTX, Sulfasalazin, and Plaquenil, three proven anti-rheumatic drugs. Group B received treatment with MTX and anti-TNF or Remicade (Infliximab), one of the most widely used biological drugs.

The analysis showed after twelve months that 26 per cent of the patients in Group A and 42 per cent of the patients in Group B responded well to the therapy. The difference was highly statistically significant and has been corroborated by several other analyses that also suggest the better efficacy of treatment strategy B. For the patients, a good response to the medicines means less pain and stiffness, better general wellbeing, improved function and a better quality of life.

Reference: The results of the study are to be presented on 12 June 2008 at an international rheumatism congress in Paris organised by the European League Against Rheumatism (EULAR). See the abstract for details of participating hospitals and scientists.

Katarina Sternudd | alfa
Further information:
http://www.karolinska.se

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

NASA keeps watch over space explosions

16.11.2018 | Physics and Astronomy

UNH scientists help provide first-ever views of elusive energy explosion

16.11.2018 | Physics and Astronomy

How the gut ‘talks’ to brown fat

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>